Signalife (Los Angeles) said it has provided notification to the American Stock Exchange (AMEX) of its intent to voluntarily withdraw its common stock from listing and trading on AMEX under AMEX Rule 18 and section 1010 of the AMEX company guide.

An application to quote and trade Signalife's common stock has been or will be shortly filed with the Over-the-Counter Bulletin Board (OTCBB), on which medium the shares traded prior to listing with AMEX, and the company intends to file a Form 25 with the SEC to formally withdraw from AMEX upon receipt of preliminary approval from the OTCBB for trading subject to SEC rules requiring a 10-day waiting period before filing such form.

Delisting from AMEX will automatically occur 10 days after filing the Form 25. As soon as information becomes available the company will announce the symbol it will trade under on the OTCBB as well as the estimated date of the start of trading.

Signalife will continu to file periodic reports with the SEC, and said that withdrawal from AMEX will not impact the pending merger with Heart One Global Research, which concurred with and sought the same result as did Signalife.

Signalife is focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring.

Isolagen back in AMEX good standing

Isolagen (Exton, Pennsylvania) said it received notice from the American Stock Exchange (AMEX) advising the company that its previously submitted plan of compliance demonstrates a reasonable course of action by the company to regain compliance with AMEX's continued listing standards, and that the delisting hearing previously scheduled for Aug. 19 has been canceled.

AMEX indicated that its decision was based upon the information disclosed in the company's report regarding the positive top-line results from the company's two pivotal, Phase III clinical studies. The company's previously submitted plan of compliance outlined its strategy to regain its compliance with AMEX's continued listing standards by Sept. 14.

Isolagen is an aesthetic and therapeutic company.

LabCorp launches kidney disease effort

Laboratory Corporation of America Holdings (LabCorp; Burlington, North Carolina) reported the launch of a national effort to combat chronic kidney disease (CKD) in North America. U.S. Senator Elizabeth Dole (R-North Carolina), a supporter of newly passed legislation to fight CKD, and representatives of the National Kidney Foundation are joining executives of LabCorp at the Kannapolis, North Carolina, launch announcing the new initiative.

The cornerstone of the effort is a program offered by LabCorp's Litholink subsidiary that provides highly nuanced, patient-specific clinical guidance to physicians based on the National Kidney Foundation's Kidney Disease Outcome Quality Initiative (KDOQI). This program is designed to support nephrologists as well as internal medicine, family practitioners, general practitioners, nurse practitioners and all other healthcare professionals who provide primary care to patients.

"LabCorp is pleased to be the first clinical lab to offer such a unique program for CKD," said David King, president/CEO of LabCorp. "With the launch of our CKD Education and Treatment Program, Litholink has developed another new and critically important tool for physicians. Our partnership with the National Kidney Foundation and other leaders in fighting CKD demonstrates the unique role that the lab can play in chronic disease prevention."

He added, "By combining critical clinical data with sophisticated information technology and expert treatment guidance, we believe our program can improve patient outcomes and save valuable healthcare dollars. Litholink's national advisory panel of CKD experts has played an active role in developing the system. Our program also fits well with the blueprint provided by the National Kidney Foundation of North Carolina for aggressively addressing CKD in North Carolina."

LabCorp specializes in diagnostic technologies and genomic testing.

American Laser Centers opens three new clinics

American Laser Centers (Minneapolis), a provider of laser hair removal and other noninvasive aesthetic services, has opened three new Minneapolis/St. Paul-area clinics in Maple Grove, Anoka (Blaine) and Burnsville. The clinics offer treatments including laser hair removal, skin rejuvenation, ReFirme skin tightening, microdermabrasion and more.

American Laser Centers' energy-based hair removal treatments provide permanent hair reduction, resulting in a high level of safety, comfort and effectiveness. Skin rejuvenation treatments at American Laser Centers include: microdermabrasion for safe, rapid skin renewal; FotoFacial to reduce sun spots and fine lines and wrinkles; ReFirme for skin tightening; and Affirm for sun damaged and acne-scarred skin.